Track topics on Twitter Track topics that are important to you
Phone: 41 (52) 630 9111
Fax: 41 (52) 630 9444
Janssen Pharmaceutical affiliate Cilag International has signed a global collaboration and license agreement with Dutch biotechnology company Argenx for cusatuzumab...Read More... The post Janssen aff...
Cilag International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, will partner with argenx to develop its cancer-fighting antibody cusatuzumab (ARGX-110), through a c...
Swiss-based Cilag, an affiliate of Janssen, the pharmaceuticals division of Johnson & Johnson, has entered into a global collaboration and license agreement with biotech company argenx to develop ...
Argenx SE licensed Janssen’s Cilag GMBH International exclusive global rights to its cusatuzumab (ARGX110) in blood cancers.
Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered into a worldwide collaboration and license agreement with argenx BVBA and argenx SE, to...
ZUG, Switzerland, December 3, 2018 /PRNewswire/ -- Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today it has Read more...
$JNJ Janssen Affiliate Cilag Enters Worldwide Collab and License Agreement with $ARGX for Cancer Immunotherapy Cusatuzumab. $300M upfront to $ARGX https://www.prnewswire.com/news-releases/janssen-affiliate-cilag-gmbh-international-enters-worldwide-collabo
$JNJ Janssen Affiliate Cilag Enters Worldwide Collab and License Agreement with $ARGX for Cancer Immunotherapy Cusatuzumab. $300M upfront to $ARGX
Cusatuzumab to be developed for #leukemia, MDS under $1.8B+ collaboration by J&J / @JanssenGlobal's Cilag and argenx ($ARGX): http://ow.ly/140N30mQtbF
These highlights do not include all the information needed to use STELARA safely and effectively. See full prescribing information for STELARA. STELARA (ustekinumab) Injection, for subcutaneous useIn...
Anemia is one of the most prevalent complications in patients with chronic kidney disease, which is believed to be caused by the insufficient synthesis of erythropoietin by the kidney. This phase III ...
This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving about 462 clinically stable hemodialysis patients aged 18 years or above suffering from anemia ...
This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged >18 years who are receiving palliative chemotherapy and who are suffering ...
Genomic studies on atrial fibrillation patients have identified polymorphisms in regions surrounding the PITX2 gene, suggesting it could be the locus responsible for atrial fibrillation. T...
Janssen-Cilag EMEA, a division of Janssen Pharmaceutica N.V., is a research-based pharmaceutical company that develops and markets innovative, high-quality pharmaceutical products and services aim...
We have published hundreds of Cilag AG news stories on BioPortfolio along with dozens of Cilag AG Clinical Trials and PubMed Articles about Cilag AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cilag AG Companies in our database. You can also find out about relevant Cilag AG Drugs and Medications on this site too.